Immunology Therapeutics
•250 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (250)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Pipeline includes immunology-focused therapies (Taltz, Omvoh, Ebglyss).
|
$816.66B |
$863.11
+2.20%
|
|
JNJ
Johnson & Johnson
TREMFYA is an immunology therapeutic with strong ongoing demand and expansion potential.
|
$454.86B |
$188.88
-0.09%
|
|
ABBV
AbbVie Inc.
Immunology therapeutics across Skyrizi, Rinvoq, Ubrelvy, and Qulipta form AbbVie’s immunology portfolio.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
AZN's immunology therapeutics portfolio targets immune-inflammatory diseases.
|
$255.44B |
$82.39
+0.06%
|
|
AMGN
Amgen Inc.
Immunology Therapeutics covers Amgen's inflammation/immune-mediated disease portfolio (e.g., UPLIZNA).
|
$160.47B |
$298.45
+2.21%
|
|
GILD
Gilead Sciences, Inc.
Gilead’s inflammation-focused initiatives and immunology-related partnerships justify Immunology Therapeutics.
|
$149.01B |
$119.77
+1.12%
|
|
PFE
Pfizer Inc.
Immunology therapeutics encompass Pfizer's broader immune-inflammatory product area beyond oncology.
|
$140.14B |
$24.66
+1.50%
|
|
BMY
Bristol-Myers Squibb Company
Immunology Therapeutics captures BMY's immune-mediated disease focus beyond oncology.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Dupixent and related assets address immunology/immune-inflammatory indications.
|
$69.08B |
$651.52
-0.39%
|
|
ZTS
Zoetis Inc.
Immunology therapeutics encompass immune-modulating approaches, including mAbs and related therapies.
|
$64.15B |
$144.07
+0.33%
|
|
ARGX
argenx SE
The company focuses on immunology/autoimmune therapies, aligning with Immunology Therapeutics.
|
$48.94B |
$818.45
-0.23%
|
|
TAK
Takeda Pharmaceutical Company Limited
Immunology therapeutics encompass TYK2 inhibitors and other immune-inflammatory therapies in Takeda's pipeline.
|
$42.61B |
$13.44
+1.59%
|
|
BIIB
Biogen Inc.
Biogen's immunology programs (felzartamab, litifilimab) position it in Immunology Therapeutics.
|
$22.62B |
$154.27
+3.11%
|
|
GMAB
Genmab A/S
Genmab's oncology focus and immunotherapy modalities align with Immunology Therapeutics.
|
$18.93B |
$28.60
-0.24%
|
|
INCY
Incyte Corporation
Opzelura and broader immunology programs address inflammatory and autoimmune conditions, aligning with Immunology Therapeutics.
|
$18.25B |
$93.49
+0.97%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab's action as a PD-1–targeted immunotherapy places Summit within Immunology Therapeutics.
|
$14.05B |
$18.91
+1.45%
|
|
ROIV
Roivant Sciences Ltd.
Immunology Therapeutics covers Roivant's FcRn and related immunology drug programs.
|
$13.59B |
$19.98
+2.07%
|
|
ELAN
Elanco Animal Health Incorporated
Immunology therapeutics focus within the pipeline (e.g., dermatology) aligns with immunology therapeutics.
|
$11.00B |
$22.14
-1.91%
|
|
BPMC
Blueprint Medicines Corporation
Mast cell disorders are immune-inflammatory; Blueprint's therapies target immune pathways, aligning with Immunology Therapeutics.
|
$8.27B |
$129.46
|
|
ABVX
Abivax S.A.
Abivax develops immunology-focused therapeutics for inflammatory diseases like ulcerative colitis and Crohn's disease.
|
$6.45B |
$102.61
-1.61%
|
|
GRFS
Grifols, S.A.
Grifols’ business includes immunoglobulin therapies and other immunology-focused plasma products, aligning with Immunology Therapeutics.
|
$6.44B |
$9.35
+2.07%
|
|
KRYS
Krystal Biotech, Inc.
KB707 immunotherapy programs align with immunology therapeutics in oncology.
|
$5.71B |
$196.63
+3.99%
|
|
TGTX
TG Therapeutics, Inc.
TG Therapeutics' business centers on immunology therapeutics, including autoimmune diseases like MS.
|
$5.52B |
$34.78
+2.23%
|
|
PTCT
PTC Therapeutics, Inc.
Inflammation platforms (vatiquinone, utreloxastat) indicate immunology therapeutics focus.
|
$5.41B |
$68.28
+0.25%
|
|
ACLX
Arcellx, Inc.
Immunology therapeutics encompasses immune-based therapies including cell therapies for cancers.
|
$4.97B |
$90.33
+3.23%
|
|
IMVT
Immunovant, Inc.
Company focuses on immunology therapeutics, including IgG-reducing biologics for autoimmune diseases.
|
$4.22B |
$24.69
-0.52%
|
|
KYMR
Kymera Therapeutics, Inc.
Immunology Therapeutics captures Kymera's focus on immune-inflammatory diseases and its pipeline targeting immune pathways.
|
$4.03B |
$61.83
+0.63%
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$3.70B |
$15.48
+1.38%
|
|
APGE
Apogee Therapeutics, Inc.
Operates in immunology therapeutics focusing on inflammatory/immune pathways (IL-13, IL-4Rα, OX40L, TSLP).
|
$3.37B |
$56.55
+0.91%
|
|
CNTA
Centessa Pharmaceuticals plc
Centessa's portfolio includes immunology/immune-oncology therapeutics via LockBody, aligning with 'Immunology Therapeutics'.
|
$3.33B |
$24.89
+2.32%
|
|
CGON
CG Oncology, Inc. Common stock
The asset is an immunotherapy modality (oncolytic immunotherapy) which fits immunology therapeutics, broadly.
|
$3.30B |
$43.28
+1.91%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.03B |
$25.32
+1.61%
|
|
ZLAB
Zai Lab Limited
Immunology therapeutics platform including bispecifics like ZL-1503 for atopic conditions and inflammatory diseases.
|
$2.83B |
$26.12
+2.37%
|
|
SRRK
Scholar Rock Holding Corporation
Immunology Therapeutics: work on immune signaling modulation via growth-factor–targeted antibodies aligns with immunology-focused therapies.
|
$2.81B |
$29.68
+1.04%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$2.74B |
$36.98
-0.83%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLS' complement-inhibiting therapies address immunology/immune-mediated diseases, aligning with the Immunology Therapeutics investable theme.
|
$2.71B |
$21.46
+3.55%
|
|
ADPT
Adaptive Biotechnologies Corporation
Immune Medicine segment focused on immunology therapeutics and immune-driven drug discovery.
|
$2.64B |
$17.36
+2.69%
|
|
IBRX
ImmunityBio, Inc.
Immunology therapeutics platform addressing immune-oncology approaches.
|
$2.12B |
$2.39
+1.27%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus's IO-focused immunology programs position it within Immunology Therapeutics.
|
$2.10B |
$19.72
-2.33%
|
|
GLPG
Galapagos N.V.
Immunology therapeutics framework, given immune-based cell therapies for oncology.
|
$2.09B |
$31.78
+1.40%
|
|
VRDN
Viridian Therapeutics, Inc.
TED and FcRn inhibitor programs place the company in Immunology Therapeutics, addressing autoimmune diseases.
|
$1.93B |
$23.64
-0.11%
|
|
MESO
Mesoblast Limited
Immunology therapeutics: anti-inflammatory immunomodulatory action across inflammatory diseases.
|
$1.92B |
$16.67
+1.46%
|
|
VERA
Vera Therapeutics, Inc.
IgA Nephropathy is an immunology/immune-inflammatory indication, aligning Vera's core immunology therapeutics strategy with Immunology Therapeutics.
|
$1.82B |
$28.44
-4.15%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$1.78B |
$13.18
+8.70%
|
|
CLDX
Celldex Therapeutics, Inc.
Celldex pursuing immunology therapeutics for mast cell–driven inflammatory diseases (CSU/CIndU/PN/EoE/AD).
|
$1.77B |
$26.70
+2.69%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP degrader platforms and IgG/IgA-targeting efforts place Biohaven in Immunology Therapeutics.
|
$1.76B |
$17.20
-1.06%
|
|
OGN
Organon & Co.
Vtama is a topical immunology dermatology therapy, aligning with immunology therapeutics.
|
$1.75B |
$6.75
+2.66%
|
|
JANX
Janux Therapeutics, Inc.
Immunology Therapeutics captures immune-oncology strategies and immune modulation within cancer.
|
$1.70B |
$28.70
+0.67%
|
|
IMCR
Immunocore Holdings plc
Pipeline includes autoimmune/inflammatory disease programs (ImmTAAI) as immune-modulating medicines.
|
$1.66B |
$33.00
+2.52%
|
|
ABCL
AbCellera Biologics Inc.
Immunology-focused therapeutics including antibodies and TCE modalities.
|
$1.66B |
$5.54
+3.36%
|
|
SYRE
Spyre Therapeutics, Inc.
Company operates in immunology therapeutics with a focus on inflammatory diseases like IBD and RA using antibody-based therapies.
|
$1.48B |
$24.47
+0.87%
|
|
UPB
Upstream Bio, Inc.
The program targets upstream immune-inflammatory pathways, consistent with Immunology Therapeutics.
|
$1.39B |
$25.86
+0.35%
|
|
ZYME
Zymeworks Inc.
Immunology Therapeutics coverage for AIID programs, including ZW1528 and related bispecific developments.
|
$1.33B |
$19.07
-0.26%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.31B |
$31.25
+4.60%
|
|
TRML
Tourmaline Bio, Inc.
TRML focuses on IL-6 mediated immune/inflammatory diseases, aligning with Immunology Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
PGEN
Precigen, Inc.
Company's immuno-oncology/immune activation therapies align with Immunology Therapeutics.
|
$1.22B |
$4.14
+2.35%
|
|
PHVS
Pharvaris N.V.
HAE/AAE treatment represents an immunology therapeutic area, aligning with Immunology Therapeutics.
|
$1.21B |
$22.21
-0.13%
|
|
CVAC
CureVac N.V.
Immunology therapeutics category applies to its immunotherapy approaches in oncology and infectious disease contexts.
|
$1.20B |
$5.34
-0.37%
|
|
INBX
Inhibrx Biosciences, Inc.
Immunology therapeutics focus (OX40 agonist) in oncology pipeline.
|
$1.18B |
$81.68
+4.04%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo's CSF-1R mechanism addresses immunology/inflammation, fitting Immunology Therapeutics.
|
$1.18B |
$13.71
+2.35%
|
|
INVA
Innoviva, Inc.
Innoviva's infectious-disease/critical-care therapeutic platform aligns with Immunology Therapeutics.
|
$1.14B |
$18.21
+1.45%
|
|
DNTH
Dianthus Therapeutics, Inc.
Company focuses on immunology therapeutics addressing autoimmune/inflammatory diseases.
|
$1.12B |
$34.96
+3.62%
|
|
SANA
Sana Biotechnology, Inc.
Autoimmune diseases are a focus (GLEAM autoimmune program; HIP platform for immune modulation).
|
$1.12B |
$4.94
+0.82%
|
|
OPK
OPKO Health, Inc.
ModeX's immunology-focused therapeutic programs align with immunology therapeutics.
|
$1.08B |
$1.34
-7.88%
|
|
ANAB
AnaptysBio, Inc.
Company develops immunology therapeutics targeting autoimmune/inflammatory diseases (e.g., rosnilimab, ANB033, ANB101).
|
$1.07B |
$36.58
+0.29%
|
|
IMTX
Immatics N.V.
Immunology therapeutics encompassing immune-oncology approaches.
|
$1.05B |
$10.19
-2.21%
|
|
XNCR
Xencor, Inc.
Autoimmune therapeutics development (e.g., TL1A, CD20/CD3) falls under immunology therapeutics.
|
$1.05B |
$14.70
+4.00%
|
|
NRIX
Nurix Therapeutics, Inc.
The company also targets autoimmune diseases in its pipeline, aligning with Immunology Therapeutics.
|
$989.25M |
$12.95
+1.33%
|
|
URGN
UroGen Pharma Ltd.
UGN-301 (anti-CTLA-4) places URGN in Immunology Therapeutics within oncology.
|
$943.82M |
$20.45
+3.02%
|
|
SEPN
Septerna, Inc.
SEP-631 is an oral small molecule NAM for MRGPRX2 in mast cell diseases, placing Septerna in the immunology therapeutics space.
|
$917.90M |
$20.54
-4.42%
|
|
PHAR
Pharming Group N.V.
Joenja (leniolisib) is an immunology therapeutic targeting APDS and related immune-dysregulation disorders.
|
$888.64M |
$13.60
+3.50%
|
|
SPRY
ARS Pharmaceuticals, Inc.
ARS Pharma's allergy/immunology-focused therapy positions it within Immunology Therapeutics.
|
$879.99M |
$8.94
+3.71%
|
|
VIR
Vir Biotechnology, Inc.
Immunology therapeutics focus due to immune-modulating T-cell engager strategies and platform-enabled immune therapies.
|
$823.90M |
$5.95
+0.34%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$805.58M |
$64.90
+3.34%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
MRT-8102 NEK7 and related programs address inflammatory/immunology indications, aligning with Immunology Therapeutics.
|
$790.40M |
$12.86
-1.19%
|
|
REPL
Replimune Group, Inc.
RP1/RPx activates the immune system, aligning with immunology therapeutics.
|
$750.05M |
$9.73
-5.07%
|
|
SVRA
Savara Inc.
Molgramostim modulates immune signaling in an autoimmune-related lung disease, fitting Immunology Therapeutics.
|
$717.27M |
$4.15
-3.49%
|
|
ATXS
Astria Therapeutics, Inc.
STAR-0310 targets the immunology pathway (OX40 antagonist), aligning with Immunology Therapeutics.
|
$712.76M |
$12.63
+0.96%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$648.46M |
$10.09
+2.85%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Strategy targets immune pathways (ITK inhibition and A2A antagonism) across immune-mediated diseases, fitting Immunology Therapeutics.
|
$620.00M |
$8.04
+3.54%
|
|
KROS
Keros Therapeutics, Inc.
TGF-β pathway modulation is inherently immunology/immune-inflammatory in nature, aligning Keros' therapies to Immunology Therapeutics.
|
$618.17M |
$15.20
+1.13%
|
|
VTYX
Ventyx Biosciences, Inc.
NLRP3 inhibitors and related immunology-focused pipeline target immunology therapeutics.
|
$607.01M |
$8.56
+1.66%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
TAVALISSE targets immune signaling (SYK) and is used for an immune-mediated hematologic condition, supporting Immunology Therapeutics.
|
$564.41M |
$31.58
-0.13%
|
|
BCYC
Bicycle Therapeutics plc
BT7480 TICA modality engages immune pathways (CD137), an immunology-oncology approach.
|
$559.30M |
$8.05
-8.05%
|
|
GOSS
Gossamer Bio, Inc.
PH-PAH/PH-ILD involve inflammatory pathways; seralutinib has anti-inflammatory/immunomodulatory actions, aligning with Immunology Therapeutics.
|
$556.89M |
$2.45
+1.24%
|
|
ABSI
Absci Corporation
ABS-101 targets TL1A in IBD, placing Absci in Immunology Therapeutics.
|
$545.95M |
$4.29
+4.77%
|
|
IMAB
I-Mab
I-Mab leverages immunotherapy approaches to reinvigorate the immune response against cancer, aligning with immunology therapeutics.
|
$533.68M |
$4.64
|
|
CMPX
Compass Therapeutics, Inc.
Immunology Therapeutics focus, aligning with immune-modulating cancer therapies.
|
$517.18M |
$3.73
+0.40%
|
|
CGEM
Cullinan Therapeutics, Inc.
Autoimmune indications and T-cell engager programs place Cullinan in Immunology Therapeutics.
|
$511.07M |
$8.66
+14.62%
|
|
RAPT
RAPT Therapeutics, Inc.
Lead programs include immunology-focused therapies (RPT904 for allergic diseases), aligning with Immunology Therapeutics.
|
$499.56M |
$30.17
+1.58%
|
|
OMER
Omeros Corporation
Company develops immunology therapeutics with complement pathway focus, aligning with immunology therapeutics.
|
$429.48M |
$7.32
-2.66%
|
|
AUTL
Autolus Therapeutics plc
Immunology therapeutics with autoimmune disease focus (e.g., LN and MS programs).
|
$412.52M |
$1.55
+2.98%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Immunology therapeutics focus; includes oncology immunotherapies.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
The company operates in immunology-focused therapeutics within the cancer immunotherapy space.
|
$388.48M |
$10.15
|
|
VIGL
Vigil Neuroscience, Inc.
TREM2 activation engages immunomodulation in the CNS, aligning with Immunology Therapeutics.
|
$375.71M |
$8.05
|
|
GALT
Galectin Therapeutics Inc.
Belapectin's immunomodulatory effects and its exploration in cancer immunotherapy align with Immunology Therapeutics.
|
$367.72M |
$5.79
+14.20%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax represents an immunotherapy approach, mapping to Immunology Therapeutics.
|
$355.83M |
$0.25
|
|
ANNX
Annexon, Inc.
Company's C1q-targeting immunology approach places it in Immunology Therapeutics.
|
$346.70M |
$3.16
+7.85%
|
|
ACIU
AC Immune S.A.
Immunology Therapeutics – immune-based therapies targeting neuroinflammation and neurodegenerative processes.
|
$337.46M |
$3.38
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Immunology therapeutics category applies to the immunotherapy approach used in CPMV's platform.
|
$336.31M |
$0.84
|
Showing page 1 of 3 (250 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
